Assessing the role of curosurf and survanta in prognosis of neonatal RDS

Due to the high incidence of respiratory distress syndrome in preterm infants and known side effects of its treatment and various effects of two types of surfactant (survanta and curosurf) this study was conducted in 1390 to compare the effect of these drugs in neonates with RDS. This historical cohort study was done on 116 neonates with respiratory distress syndrome in Shohada Hospital. Babies with heart abnormalities and other fatal anomalies were excluded. 54 infants were treated with intratracheal Svrvanta and 62 in the control group were treated with intratracheal curosurf. The two groups were compared in terms of birth weight and gestational age، treatment outcomes، mortality، pneumothorax، pulmonary hemorrhage، ventilator-associated pneumonia، intraventricular hemorrhage، and patent ductus arteriosus using Fisher tests and clinical judgment. Gender، gestational age، birth weight، prenatal corticosteroids، mode of delivery and Apgar score at one minute was not significantly different between the two groups. Mortality in the control group (Svrvanta) was 15%، and in cases (curosurf) was 14. 5% (p= 0. 849). 14. 5% of Corusurf and 20. 4% of Survanta group had received more than one dose of surfactant (p= 0. 405). Statistically significant difference in the incidence of pneumothorax، pulmonary hemorrhage، ventilator-associated pneumonia، patent ductus arteriosus، intraventricular hemorrhage، and duration of mechanical ventilation was not seen among the two groups. ‍ It seems that two types of surfactant have similar effects in prognosis of respiratory distress syndrome. However more researches are needed due to high incidence of RDS in preterm infants and need to appropriate treatment.